(Reuters) – The German pharmaceutical BioNTech and the American giant Pfizer they said on Wednesday that in the second half of this year Human trials of next-generation vaccines that protect against a wide variety of coronaviruses will begin.
Experimental work, which goes beyond the current approach, includes T-cell-enhancing injections, designed to primarily protect against serious illness if the virus becomes more dangerousas well as others of pancoronaviruswhich protect against the broader family of viruses and their mutations.
In presentation slides posted on BioNTech’s website for its investor day, the German biotech company said that its goal is to “provide lasting variant protection.”
The two partners, manufacturers of the COVID-19 vaccine most widely used in the Western world, are currently discussing, with regulators, improved versions of their established vaccine to better protect against the omicron variant and its sublineages.
The persistent mutation of the virus into new variants that more easily evade the protection of the vaccineas well as the decrease in human immunological memory, have added urgency to the search by companies, governments and health organizations for more reliable protection tools.
As part of an effort to further boost its business in infectious diseases, BioNTech said it is independently working on precision antibiotics that kill superbugs that have become resistant to currently available drugs.
The antibiotics developer based in Single has worked on enzymes, produced by bacteria-killing viruses, that break through the bacterial cell wall.
Additional reporting by Patricia Weiss; edited in Spanish by Marion Giraldo.
We need your help:
Like you, thousands of Cubansthey read and support the independent journalism of CiberCuba. Our editorial independence begins with our economic independence: no organization from any country finances CyberCuba. We make our own agenda, we publish our opinions and we give a voice to all Cubans, without external influences.
Our newspaper has been financed until today only through advertising and own funds, but that limits what we can do. This is why we ask for your help. Your financial contribution will allow us to do more investigative journalism actions and increase the number of collaborators who report from the island, while maintaining our editorial independence. Any contribution, big or small, will be very valuable for our future. From only $5 and with just one minute of your time you can collaborate with CiberCuba. Thanks.